// App-Quantinova.ai

2139 : Sustained Response to Guselkumab Regardless of Baseline Demographic, Disease, and Medication Characteristics in Patients with Active Psoriatic Arthritis and an Inadequate Response to TNF Inhibitors: Results from a Phase 3b Trial

Researchers

Presenter

  • Iain B McInnes

Principal Investigators

  • Philipp Sewerin

  • Mohamed Sharaf

  • Michela Efficace

  • May Shawi

  • Michelle Perate

  • Miriam Zimmermann

  • Laura Coates

Medical Centers

  • Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom

  • Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany

  • Johnson & Johnson, Middle East FZ LLC, Dubai, United Arab Emirates

  • Janssen Cilag SpA, Imperia, Italy

  • Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA

  • Janssen Scientific Affairs, Horsham, PA

  • Janssen, Scientific Affairs, LLC, Zug, Switzerland

  • Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences,, Oxford University Hospitals NHS Trust, Oxford, UK, Oxford, United Kingdom

Locations

  • United Kingdom

  • Germany

  • United Arab Emirates

  • Italy

  • United States

  • Switzerland

Companies

  • JB Medical Ltd.

Study Components

Therapeutic Area

  • Musculoskeletal

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriatic arthritis

  • Psoriasis

Biomarkers

  • Malondialdehyde

  • Tumor necrosis factor

  • Body mass index

Drug/Treatment

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Randomized

  • Cross Over

Phase

  • III

Study Id's

  • NCT03796858

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved